The NMPA approval is a clear positive catalyst that de-risks the ex-U.S. commercial thesis for etripamil. The immediate $2M payment is small relative to the $147M market cap, but the $98M milestone potential and 18% royalty stream represent meaningful upside if Everest executes on the China launch. Monitor for updates on the ongoing Phase 3 AFib-RVR trial and any U.S. sales trajectory data, which remain the primary value drivers.
Price Chart
Executive Summary
China's NMPA approved Milestone's etripamil nasal spray (CARDAMYST) for PSVT in adults, marking the first regulatory approval outside the U.S. The approval triggers a $2.0 million milestone payment to Milestone, with potential for up to $98.0 million in additional milestones and tiered royalties of up to 18% on future sales in Greater China. This expands the commercial footprint for Milestone's lead asset into a market with an estimated 3-6 million diagnosed PSVT patients, though near-term revenue impact is modest given the early-stage milestone payment and uncertain ramp of Chinese sales.
Key Facts
- China's NMPA approved etripamil nasal spray for PSVT in adults, the first regulatory approval outside the U.S.
- Approval triggers a $2.0 million milestone payment to Milestone Pharmaceuticals.
- Milestone is eligible for up to $98.0 million in commercial and development milestones and tiered royalties of up to 18% on future sales in Greater China.
- The approval was based on the global Phase 3 RAPID study and the China-specific Phase 3 JX02002 study, which met its primary endpoint (HR=3.002, p=0.0005).
- Everest Medicines will lead commercialization in Greater China (Mainland China, Hong Kong, Macau, Taiwan).
- Estimated 3-6 million people in China are diagnosed with PSVT.
Financial Impact
Immediate $2.0 million milestone payment; potential for up to $98.0 million in additional milestones plus tiered royalties up to 18% on future sales.
Risk Factors
- Commercial execution risk in China by Everest Medicines is unproven for this product.
- U.S. CARDAMYST sales ramp remains uncertain and is the primary near-term value driver.
- Potential for slower-than-expected milestone achievement or royalty generation from China.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-105052 |
| Document: tm2624766d1_8k.htm | 0001104659-26-105052 |
| Document: 0001104659-26-105052-index-headers.html | 0001104659-26-105052 |
| Document: 0001104659-26-105052-index.html | 0001104659-26-105052 |
| Document: 0001104659-26-105052.txt | 0001104659-26-105052 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | 8-K | $1.20 $0.7794 | ▼ −35.05% | ▼ −35.65% | $0.6480 (−46.00%) |
Aug 21, 2026 9w ago | Press Release | $1.06 $0.9178 | ▼ −13.00% | ▼ −12.48% | $0.6480 (−38.58%) |
Aug 12, 2026 10w ago | 8-K | $1.13 $1.05 | ▲ +6.67% | ▲ +4.77% | $0.6480 (+42.40%) |
May 26, 2026 21w ago | EFFECT | $1.40 $1.28 | ▲ +8.57% | ▲ +6.62% | $0.6480 (+53.71%) |
May 13, 2026 23w ago | S-3 | $1.63 $1.27 | ▲ +22.09% | ▲ +21.23% | $0.6480 (+60.25%) |
May 13, 2026 23w ago | 8-K | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6480 (−62.33%) |
May 13, 2026 23w ago | Press Release | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6480 (−62.33%) |
Mar 20, 2026 31w ago | Press Release | $1.36 $2.04 | ▲ +50.00% | ▲ +40.68% | $0.6480 (−52.35%) |
Mar 16, 2026 32w ago | Press Release | $1.69 $2.03 | ▲ +20.12% | ▲ +16.34% | $0.6480 (−61.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers